4SC - Crunchbase Company Profile & Funding

Q: Where is 4SC's headquarters?

4SC is located in Planegg, Bayern, Germany.

Q: Who invested in 4SC?

4SC has 9 investors including Santo Holding And Wellington Partners.

Q: When was the last funding round for 4SC?

4SC closed its last funding round on obfuscated from a Post-IPO Equity round.

Overview

4SC

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

See more interactive data and historical milestones on desktop for the best experience

About 4SC

CB Rank

224746

4SC discovers and develops targeted, small-molecule drugs for the treatment of cancer and autoimmune diseases.

Founded

obfuscation

Public

Post-IPO Equity

Planegg, Bayern, Germany

51-100

www.4sc.de/

Biopharma

Biotechnology

Therapeutics

Funding Rounds

Post-IPO Equity

OBF

obfuscation

Post-IPO Equity

OBF

obfuscation

Post-IPO Equity

OBF

obfuscation

Key People

Jason Loveridge: Chief Executive Officer
Susanne Danhauser-Riedl: Chief Medical Officer

Details

Legal Name

4SC AG

Operating Status

Active

Stock Symbol

FRA:VSC

Company Type

For Profit

About the Company

4SC discovers and develops targeted, small-molecule drugs for the treatment of cancer and autoimmune diseases in indications with high unmet medical needs. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious, and provide a better quality of life.

Phone Number

+490897007630

Contact Email

ursula.herz@4sc.com

Predictions & Insights

Products & Services

Resminostat (Kinselby)

An oral histone deacetylase (HDAC) inhibitor drug candidate for treating various cancers, including cutaneous T-cell lymphoma (CTCL).

Domatinostat (4SC-202)

An oral class I-specific HDAC inhibitor designed to enhance immune response against cancer, investigated for use in combination with checkpoint inhibitors.

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Post-IPO Equity - 4SC	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - 4SC	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - 4SC	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - 4SC	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - 4SC	—	obfuscated obfuscation	—	Post-IPO Equity

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Post-IPO Equity - 4SC	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - 4SC	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - 4SC	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - 4SC	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - 4SC	—	obfuscated obfuscation	—	Post-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
Santo Holding	—	Post-IPO Equity - 4SC	—
Santo Holding	—	Post-IPO Equity - 4SC	—
Santo Holding	—	Post-IPO Equity - 4SC	—
Santo Holding	—	Post-IPO Equity - 4SC	—
Santo Holding	—	Post-IPO Equity - 4SC	—

Investments

Investment Breakdown

Number of Investments

See investment data for this company, with details on deal size, industry, stage, and more.

Announced Date	Organization Name	Lead Investor	Funding Round	Money Raised
obfuscated obfuscation	Panoptes Pharma	No	Seed Round - Panoptes Pharma	obfuscated obfuscation
obfuscated obfuscation	Panoptes Pharma	No	Seed Round - Panoptes Pharma	obfuscated obfuscation
obfuscated obfuscation	Panoptes Pharma	No	Seed Round - Panoptes Pharma	obfuscated obfuscation
obfuscated obfuscation	Panoptes Pharma	No	Seed Round - Panoptes Pharma	obfuscated obfuscation
obfuscated obfuscation	Panoptes Pharma	No	Seed Round - Panoptes Pharma	obfuscated obfuscation

Investment Breakdown

Number of Investments

See investment data for this company, with details on deal size, industry, stage, and more.

Announced Date	Organization Name	Lead Investor	Funding Round	Money Raised
obfuscated obfuscation	Panoptes Pharma	No	Seed Round - Panoptes Pharma	obfuscated obfuscation
obfuscated obfuscation	Panoptes Pharma	No	Seed Round - Panoptes Pharma	obfuscated obfuscation
obfuscated obfuscation	Panoptes Pharma	No	Seed Round - Panoptes Pharma	obfuscated obfuscation
obfuscated obfuscation	Panoptes Pharma	No	Seed Round - Panoptes Pharma	obfuscated obfuscation
obfuscated obfuscation	Panoptes Pharma	No	Seed Round - Panoptes Pharma	obfuscated obfuscation